pbsv_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 1, 2015
Pharma-Bio Serv, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
0-50956
|
20-0653570
|
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
6 Road 696, Dorado, Puerto Rico
|
00646
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(787) 278-2709
|
|
(Registrant’s Telephone Number, Including Area Code)
|
| |
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 1, 2015, Pharma-Bio Serv, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders. Below is a summary of the proposals and corresponding votes.
Kirk Michel and Dov Perlysky were elected as Class II directors to serve for a term until the 2018 Annual Meeting of Stockholders or until a successor is duly elected and qualified. Messrs. Michel and Perlysky received the following votes:
|
Nominee
|
For
|
Withheld
|
|
Kirk Michel
|
13,284,861
|
7,110
|
|
Dov Perlysky
|
13,284,871
|
7,100
|
There were 4,466,998 broker non-votes on this proposal.
The ratification of the selection of Horwath Velez & Co. PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2015 received the following votes:
|
For
|
Against
|
Abstain
|
|
17,756,859
|
2,110
|
0
|
There were no broker non-votes on this proposal.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
PHARMA-BIO SERV, INC. |
|
| |
|
|
|
|
Date: May 5, 2015
|
By:
|
/s/ Pedro J. Lasanta |
|
| |
|
Pedro J. Lasanta |
|
| |
|
Chief Financial Officer, Vice President Finance and Administration and Secretary
|
|
| |
|
|
|
3